Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy

被引:39
作者
Pierorazio, Phillip M. [1 ]
Ross, Ashley E. [1 ]
Lin, Brian M. [1 ]
Epstein, Jonathan I. [1 ]
Han, Misop [1 ]
Walsh, Patrick C. [1 ]
Partin, Alan W. [1 ]
Pavlovich, Christian P. [1 ]
Schaeffer, Edward M. [1 ]
机构
[1] Johns Hopkins Univ, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA
基金
美国国家卫生研究院;
关键词
prostate cancer; high-risk; Gleason sum; outcomes; TUMOR VOLUME; RETROPUBIC PROSTATECTOMY; CANCER; MEN; SURVIVAL; RADIOTHERAPY; RECURRENCE; THERAPY; ANTIGEN; MANAGEMENT;
D O I
10.1111/j.1464-410X.2012.10986.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To investigate preoperative characteristics that distinguish favourable and unfavourable pathological and clinical outcomes in men with high biopsy Gleason sum (8-10) prostate cancer to better select men who will most benefit from radical prostatectomy (RP). PATIENTS AND METHODS The Institutional Review Board-approved institutional RP database (1982-2010) was analysed for men with high-Gleason prostate cancer on biopsy; 842 men were identified. The 10-year biochemical-free (BFS), metastasis-free (MFS) and prostate cancer-specific survival (CSS) were calculated using the Kaplan-Meier method to verify favourable pathology as men with Gleason <8 at RP or <= pT3a compared with men with unfavourable pathology with Gleason 8-10 and pT3b or N1. Preoperative characteristics were compared using appropriate comparative tests. Logistic regression determined preoperative predictors of unfavourable pathology. RESULTS There was favourable pathology in 656 (77.9%) men. The 10-year BFS, MFS and CSS were 31.0%, 60.9% and 74.8%, respectively. In contrast, men with unfavourable pathological findings had significantly worse 10-year BFS, MFS and CSS, at 4.3%, 29.1% and 52.3%, respectively (all P < 0.001). In multivariable logistic regression, a prostate-specific antigen (PSA) concentration of >10 ng/mL (odds ratio [OR] 2.24, 95% confidence interval [CI] 1.38-3.62, P = 0.001), advanced clinical stage (>= cT2b; OR 2.55, 95% CI 1.55-4.21, P < 0.001), Gleason pattern 9 or 10 at biopsy (OR 2.55, 95% CI 1.59-4.09, P < 0.001), increasing number of cores positive with high-grade cancer (OR 1.16, 95% CI 1.01-1.34, P = 0.04) and >50% positive core involvement (OR 2.25, 95% CI 1.17-4.35, P = 0.015) were predictive of unfavourable pathology. CONCLUSIONS Men with high-Gleason sum at biopsy are at high risk for biochemical recurrence, metastasis and death after RP; men with high Gleason sum and advanced pathological stage (pT3b or N1) have the worst prognosis. Among men with high-Gleason sum at biopsy, a PSA concentration of > 10 ng/mL, clinical stage >= T2b, Gleason pattern 9 or 10, increasing number of cores with high-grade cancer and >50% core involvement are predictive of unfavourable pathology.
引用
收藏
页码:1122 / 1128
页数:7
相关论文
共 26 条
[1]  
[Anonymous], EUR UROL
[2]   Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10 [J].
Bastian, Patrick J. ;
Gonzalgo, Mark L. ;
Aronson, William J. ;
Terris, Martha K. ;
Kane, Christopher J. ;
Amling, Christopher L. ;
Presti, Joseph C., Jr. ;
Mangold, Leslie A. ;
Humphreys, Elizabeth ;
Epstein, Jonathan I. ;
Partin, Alan W. ;
Freedland, Stephen J. .
CANCER, 2006, 107 (06) :1265-1272
[3]   RESULTS OF CONSERVATIVE MANAGEMENT OF CLINICALLY LOCALIZED PROSTATE-CANCER [J].
CHODAK, GW ;
THISTED, RA ;
GERBER, GS ;
JOHANSSON, JE ;
ADOLFSSON, J ;
JONES, GW ;
CHISHOLM, GD ;
MOSKOVITZ, B ;
LIVNE, PM ;
WARNER, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (04) :242-248
[4]   Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE) [J].
Cooperberg, MR ;
Lubeck, DP ;
Mehta, SS ;
Carroll, PR .
JOURNAL OF UROLOGY, 2003, 170 (06) :S21-S25
[5]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974
[6]   Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer [J].
Grossfeld, GD ;
Latini, DM ;
Lubeck, DP ;
Mehta, SS ;
Carroll, PR .
JOURNAL OF UROLOGY, 2003, 169 (01) :157-163
[7]   Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy - The 15-year Johns Hopkins experience [J].
Han, M ;
Partin, AW ;
Pound, CR ;
Epstein, JI ;
Walsh, PC .
UROLOGIC CLINICS OF NORTH AMERICA, 2001, 28 (03) :555-+
[8]   Is tumor volume an independent prognostic factor in clinically localized prostate cancer? [J].
Kikuchi, E ;
Scardino, PT ;
Wheeler, TM ;
Slawin, KM ;
Ohori, M .
JOURNAL OF UROLOGY, 2004, 172 (02) :508-511
[9]   Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology Practice Guideline [J].
Loblaw, D. Andrew ;
Virgo, Katherine S. ;
Nam, Robert ;
Somerfield, Mark R. ;
Ben-Josef, Edgar ;
Mendelson, David S. ;
Middleton, Richard ;
Sharp, Stewart A. ;
Smith, Thomas J. ;
Talcott, James ;
Taplin, Maryellen ;
Vogelzang, Nicholas J. ;
Wade, James L., III ;
Bennett, Charles L. ;
Scher, Howard I. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1596-1605
[10]   What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer? [J].
Loeb, Stacy ;
Schaeffer, Edward M. ;
Trock, Bruce J. ;
Epstein, Jonathan I. ;
Humphreys, Elizabeth B. ;
Walsh, Patrick C. .
UROLOGY, 2010, 76 (03) :710-714